![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bbi Hldgs | LSE:BBI | London | Ordinary Share | GB00B00M4S16 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 185.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1282E BBI Holdings PLC 19 September 2007 BBI HOLDINGS PLC FDA clearance for Verax test BBI Holdings Plc ('BBI'), the AIM listed developer and manufacturer of rapid result diagnostic tests and reagents for the diagnostic industry, announces that Verax Biomedical Inc.'s 510(k) application for its Platelet PGD test has been accepted by the U.S. Food and Drug Administration (FDA). The FDA clearance of the test permits Verax to market the device. With an estimated 10 million platelet units transfused each year into patients in North America, Europe and Asia, Verax anticipates a strong worldwide demand for their Platelet PGD Test. In March 2006 BBI signed a 10-year contract with Verax to provide gold colloid and manufacturing services for the test and Abbott Diagnostics have signed a worldwide exclusive agreement to market and distribute the product. The Verax PGD Platelet test, which had been developed in conjunction with BBI, is a rapid, easy-to-use disposable test which can detect bacterial contamination of blood platelets in less than 30 minutes. Bacterial contaminants in platelets and red blood cells represent the greatest infectious risk in transfusion medicine today, with over 17 million patients receiving 60 million units of blood annually in the US, Europe and Asia at risk of contamination. No practical methods are currently available to address the threat of bacterial contaminants in blood and the Verax PGD Platelet test is the only point of care test at the clinical trial stage. A method for limiting and detecting bacterial contamination in platelet components has been required by the blood banking industry since March 2004. Commenting, Julian Baines CEO of BBI said: "The FDA clearance is an important milestone for the Platelet PGD Test which BBI has been developing with Verax since August 2002. "Although initial volumes are expected to be modest, as the test is introduced to the market, it is clear that Verax believe that the potential market for this product in substantial. BBI is well placed in terms of our 10-year manufacturing contract and our capacity to produce large volumes of tests to benefit enormously from demand for this product." ENDS For further information please contact: BBI Holdings plc Landsbanki Securities (UK) Ltd Parkgreen Communications Ltd Julian Baines, CEO Sindre Ottesen Paul McManus Tel: 029 2074 7232 Fred Walsh Tel: 020 7479 7933 Tel: 020 7426 9000 Mob. 07980 541 893 www.bbigold.com Email: paul.mcmanus@parkgreenmedia.com Background notes: About BBI Holdings PLC (AIM: BBI): BBI is a leading supplier of products and services to the global diagnostic and healthcare industries. BBI floated on AIM on 28 April 2004 at 47p. BBI operates in three core areas: 1. BBInternational (diagnostics) Incorporating: British Biocell, Cardiff, UK BBI Dundee (formerly Alchemy Laboratories), Dundee, UK BBI Research, Madison, Wisconsin, USA Qnostics, Glasgow, UK BBI manufactures superior quality gold reagents which are used to bind with specific antibodies or antigens, which are used in diagnostic tests to provide a positive or negative visual signal. BBI also provides contract product development services for leading diagnostic companies using its expertise to develop rapid result diagnostic tests. BBI also manufactures rapid result diagnostic tests in the UK and the US. Rapid test manufacture involves placing conjugate onto a pad or strip and enclosing this within a preformed plastic package 'housing' designed to the customer's specifications. BBI's Qnostics division supplies molecular quality control reagents to the global market place. www.bbigold.com 2. BBI Enzymes Incorporating: Biozyme, Blaenavon, UK Seravac, Cape Town, S Africa. Theratase was acquired by BBI in May 2007 to form BBI's enzyme division. Biozyme and Seravac are leading manufacturers and suppliers of high quality specialist natural enzymes to the medical diagnostics industry. Enzymes are proteins which drive complex reactions that occur in all living organisms. Their high specificity and dramatic catalytic activity has been exploited within the diagnostic industry. www.biozyme.com www.seravac.com 3. BBI Healthcare (diabetes) Brands: GlucoGel SensoCard Plus GlucoTabs In April 2004 BBI acquired Hypostop (now renamed GlucoGel in the UK). GlucoGel is an easy to use dextrose gel which is included in the National Institute for Clinical Excellence's (NICE) treatment guideline for hypoglycaemia. BBI Healthcare was founded in April 2006 to manage the sales and marketing of GlucoGel, and build a diabetes care product portfolio. In July 2006 BBI acquired the UK's only talking blood glucose meter for the visually impaired called SensoCard Plus. The acquisition gives BBI exclusive distribution rights for within the UK, US, Canada and India. www.bbihealthcare.com This information is provided by RNS The company news service from the London Stock Exchange END MSCEASNNFELXEFE
1 Year Bbi Holdings Chart |
1 Month Bbi Holdings Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions